8-K - Omeros Corporation | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Omeros Corporation reported Q4 and full-year 2025 financial results, including $86.5 million Q4 net income driven by $237.6 million zaltenibart transaction gain with Novo Nordisk, FDA approval of YARTEMLEA, and strengthened balance sheet with $171.8 million cash.

Key Takeaways

1Q4 2025 net income $86.5M ($1.22/share) vs. $31.4M loss prior year, driven by $237.6M zaltenibart sale gain offset by $136.0M non-cash charge.

2Full-year 2025 net loss $3.4M ($0.05/share) vs. $156.8M prior year; non-GAAP adjusted net income $133.4M ($2.10/share).

3Closed zaltenibart deal with Novo Nordisk for $240M upfront, up to $1.81B milestones, high single- to high-teens royalties.

4Repaid $67.1M term loan and $17.1M 2026 notes; debt down 47% to $87.9M at Dec 31, 2025.

5Cash $171.8M at Dec 31, 2025; FDA approved YARTEMLEA for TA-TMA, U.S. launch underway.

6EMA MAA for YARTEMLEA under review, decision mid-2026.

Current Report Details

Event Type

Other Event

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events

Other Event

Results of Operations

Fourth Quarter 2025

Metric	Value	Basis	Prior Period
Net Income	$86.50	GAAP	$-31.40
Net Income per Share	$1.22	GAAP	$-0.54
Net Income	$-3.40	GAAP	$-156.80
Net Income per Share	$-0.05	GAAP	$-2.70
Non-GAAP Adjusted Net Income	$222.50	Non-GAAP
Non-GAAP Adjusted Net Income per Share	$3.14	Non-GAAP
Non-GAAP Adjusted Net Income	$133.40	Non-GAAP
Non-GAAP Adjusted Net Income per Share	$2.10	Non-GAAP
OMIDRIA Royalties	$9.20		$10.10

Transaction Details

Debt / Financing

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1